Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

Recruiting Observational Study
Hepatocellular Cancer (HCC)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
35 and older
Sex
Any
Study type
Observational
Participants needed
4,500 (estimated)
Sponsor
Zhongshan People's Hospital, Guangdong, China · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head tr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Voluntarily sign the informed consent form. * Household registration in Zhongshan City, Guangdong Province. * Aged 35 and above. * Positive screening result for Hepatitis B surface antigen (HBsAg). Exclusion Criteria: * Previous history of liver cancer or liver transplantati…
Contacts

Mingfang Ji, MD

86-0760-89880417

jmftbh@sina.com

CONTACT